Neurocrine Biosciences Inc (NBIX) Quarterly Institutional 13F Update (Q2 2026)

NBIX ranks #683 out of 37503 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

NBIX is a top-conviction position for Vestal Point Capital, LP — at 7.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in NBIX belongs to BlackRock, Inc., but the position matters far more to Vestal Point Capital, LP, who has 7.4% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Jacobs Levy Equity Management, Inc has added to its NBIX position for two straight quarters, increasing it by $117.4M to reach $122.4M today.

Wellington Management Group LLP has trimmed its NBIX position for two straight quarters, cutting it by $241.6M while still holding $5.8M.

NBIX is down 1.2% today, but institutions show net buying of $3.7B this quarter — a divergence between today's price move and the underlying institutional flow.

NBIX posted net income of $705.5M over the trailing twelve months, and currently trades at a P/E of 22.4.

• Profitable — net income of $705.5M over the trailing twelve months
• Revenue grew 34.4% year over year
• Net income improved year over year, from $348.3M to $705.5M
• Generated $782.7M in positive operating cash flow
• Current ratio of 3.39x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.42x equity — within a conventional range